CC - Analyst Finds It Difficult To Make Numeric Assumptions For Chemours: Here's Why | Benzinga
BMO Capital Markets analyst John P. McNulty downgraded The Chemours Company (NYSE:CC) to Underperform from Outperform at a lowered price target of $19 (from $45).
The analyst re-rated the stock after the company disclosed management changes and further delay in filing its 10-K.
This week, the company said it is delaying its fourth quarter results and 10-K, which was previously expected on February 28 and February 29, 2024, respectively.
Related: Chemours Stock Tumbles As ...